(19) World Intellectual Property Organization

International Bureau



(43) International Publication Date 23 December 2004 (23.12.2004)

(10) International Publication Number WO 2004/110434 A1

- (51) International Patent Classification⁷: A61K 31/4025, 31/4015, C07D 207/26, 409/12, 409/14, A61P 7/00
- (21) International Application Number:

PCT/EP2004/006591

17 June 2004 (17.06.2004) (22) International Filing Date:

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0314370.8

19 June 2003 (19.06.2003)

- (71) Applicant (for all designated States except US): GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford Middlesex UB6 0NN (GB).
- (72) Inventors; and
- (72) Inventors; and
 (73) Inventors; and
 (75) Inventors/Applicants (for US only): BORTHWICK, Alan, David [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY (GB). KLEAN-THOUS, Savvas [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY (GB).

 SENGER, Stefan [DE/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY (GB).

 SMITH, Ian, Edward, David [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY (GB).

 SMITH, Ian, Edward, David [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY (GB).

 For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

 (54) Title: 2-PYRROLIDONE DERIVATIVES AND USE THEREOF AS FACTOR XA INHIBITORS

 (57) Abstract: The invention relates to compounds of formula (I), and/or pharmaceutically acceptable derivative thereof. The invention also relates to processes for the preparation of compounds of formula (I), pharmaceutical compositions containing compounds of formula (I) and to the use of compounds of formula (I) in medicine, particularly in the amelioration of a clinical condition for

- (74) Agent: BAKER, Suzanne, Jane; GlaxoSmithKline, Corporate Intellectual Property (CN925.1), 980 Great West Road, Brentford Middlesex TW8 9GS (GB).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,

$$\begin{array}{c|c}
R^{2} & R^{1} \\
N-S & O \\
O & O \\
N-Y-R^{4} \\
R^{3}
\end{array}$$
(1)

tion also relates to processes for the preparation of compounds of formula (I), pharmaceutical compositions containing compounds of formula (I) and to the use of compounds of formula (I) in medicine, particularly in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.